Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.1.02009
European Journal of Endocrinology, Vol 153, Issue 5, 701-709
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vieira, J. M.
Right arrow Articles by Leite, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vieira, J. M.
Right arrow Articles by Leite, V.
EXPERIMENTAL STUDY

Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop

Joaquim Miguel Vieira1, Susana C Rosa Santos1, Carla Espadinha1, Isabel Correia1, Tibor Vag1, Cristina Casalou1, Branca Maria Cavaco1, Ana Luiísa Catarino2, Sérgio Dias1 and Valeriano Leite1,3

1 Centro de Investigação de Patobiologia Molecular (CIPM), 2 Departmento de Patologia Morfológica, Instituto Português de Oncologia Francisco Gentil – Centro Regional de Oncologia de Lisboa (CROL), S.A, Rua Professor Lima Basto, 1099-023 Lisboa, Portugal and 3 Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisboa, Portugal

(Correspondence should be addressed to V Leite, CIPM, Instituto Português de Oncologia Francisco Gentil; Email: vleite{at}ipolisboa.min-saude.pt)

Objective: The aim of this study was to clarify the role of vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) pathways in thyroid tumourigenesis.

Methods: We examined VEGF, VEGFR-1 and VEGFR-2 expression on 34 papillary thyroid carcinomas (PTCs), 18 follicular thyroid carcinomas (FTCs), eight poorly differentiated thyroid carcinomas (PDTCs) and on a thyroid tumour-derived cell line (NPA'87) by immunohistochemistry, reverse transcriptase PCR, immunofluorescence and Western blotting.

Results: We have demonstrated that VEGF expression was significantly (P < 0.05) more prevalent in PTCs (79%) than in FTCs (50%) or PDTCs (37%). Similarly, 76% of PTCs, 83% of FTCs and 25% of PDTCs expressed VEGFR-1, whereas 68% of PTCs, 56% of FTCs and 37% of PDTCs expressed VEGFR-2. Coexpression of VEGF and its receptors was observed in 50% of PTCs, 39% of FTCs and 12% of PDTCs, raising the possibility that VEGF may signal in an autocrine loop in these neoplasias, as observed previously for other types of cancer. In agreement with the idea that autocrine VEGF signalling plays an important role in thyroid carcinogenesis, the blockade of either VEGF or its receptors with neutralizing antibodies significantly reduced cell viability and increased apoptosis levels of the VEGFR-positive thyroid tumour cell line NPA'87.

Conclusions: Our results highlight a previously undefined VEGF autocrine action in thyroid carcinomas which could play a crucial role in tumour cell survival and could represent a useful therapeutic target for thyroid tumours.




This article has been cited by other articles:


Home page
 NEJMHome page
S. I. Sherman, L. J. Wirth, J.-P. Droz, M. Hofmann, L. Bastholt, R. G. Martins, L. Licitra, M. J. Eschenberg, Y.-N. Sun, T. Juan, et al.
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
N. Engl. J. Med., July 3, 2008; 359(1): 31 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Balthasar, N. Bergelin, C. Lof, M. Vainio, S. Andersson, and K. Tornquist
Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells
Endocr. Relat. Cancer, June 1, 2008; 15(2): 521 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
S. M. Wiseman, O. L. Griffith, S. Deen, A. Rajput, H. Masoudi, B. Gilks, L. Goldstein, A. Gown, and S. J. M. Jones
Identification of Molecular Markers Altered During Transformation of Differentiated Into Anaplastic Thyroid Carcinoma
Arch Surg, August 1, 2007; 142(8): 717 - 729.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
N. Holtkamp, N. Ziegenhagen, E. Malzer, C. Hartmann, A. Giese, and A. von Deimling
Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme
Neuro-oncol, July 1, 2007; 9(3): 291 - 297.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
C. Ferretti, L. Bruni, V. Dangles-Marie, A.P. Pecking, and D. Bellet
Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts
Hum. Reprod. Update, March 1, 2007; 13(2): 121 - 141.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. S. Kim, J. A. Franklyn, K. Boelaert, M. C. Eggo, J. C. Watkinson, and C. J. McCabe
Pituitary Tumor Transforming Gene (PTTG) Stimulates Thyroid Cell Proliferation via a Vascular Endothelial Growth Factor/Kinase Insert Domain Receptor/Inhibitor of DNA Binding-3 Autocrine Pathway
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4603 - 4611.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.